Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2016 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results

NEWARK, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases...
March 28, 2016 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces the Appointment of Paul F. Truex and Robert J. Weiland to its Board of Directors

NEWARK, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced the appointment of Paul F. Truex and Robert J. Weiland to the company’s Board of...
March 28, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology

NEWARK, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced the online publication of its Phase 2b study of arhalofenate, a novel dual-acting...
March 22, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces the Appointment of Dr. Evan Stein, M.D., Ph.D., to its Board of Directors

NEWARK, Calif., March 22, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced the appointment of Dr. Evan Stein, M.D., Ph.D., to the company’s Board of Directors...
March 21, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay to Announce Fourth Quarter and Year-End 2015 Financial Results on Tuesday, March 29

NEWARK, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...
March 17, 2016 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia

NEWARK, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced top line results from its pilot Phase 2 clinical study of MBX-8025 in patients with...
March 03, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Two Upcoming Investor Conferences in March

NEWARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...
February 02, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at the BIO CEO & Investor Conference

NEWARK, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...
January 20, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate

NEWARK, Calif., Jan. 20, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...
January 06, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at the Biotech Showcase 2016

NEWARK, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with...